PD Therapeutics 2009: Agenda & Speakers

The Michael J. Fox Foundation for Parkinson’s Research & The New York Academy of Sciences
Parkinson’s Disease Therapeutics Conference
New York, NY
September 30, 2009

Sept 30, 2009

 

8.00

Breakfast

8.30 – 8.45

Welcome by J. William Langston, MD

8.45 – 10.30

Novel Therapeutic Targets

Mathias Baehr, MD, University Hospital Göttingen
“Granulocyte-colony stimulating factor (G-CSF) as a neuroprotective therapy for Parkinson's disease”  Abstract

P. Jeffrey Conn, PhD, Vanderbilt University 
“Discovery of mGluR4 Potentiators for Symptomatic and Disease-Modifying Treatment of PD” Abstract Video

 David Bumcrot, PhD, Alnylam Pharmaceuticals, Inc.
“Therapeutic Development of siRNA Targeting Alpha-Synuclein” Abstract

10.30 – 11.00

Networking Break/Poster Viewing

11:00 – 12.00

Novel Therapeutic Targets (cont’d)

David Standaert, MD, PhD, University of Alabama at Birmingham
“Validation of VPS41, A Protein involved in Lysosomal Trafficking, as a Target for Parkinson Disease Therapy” Abstract Video

Gretchen L. Snyder, PhD, Intra-Cellular Therapies, Inc.  
“Novel Phosphodiesterase Inhibitors for Parkinson's Disease” Abstract Video

12.00 – 1.15

Lunch/Poster Viewing

1.15 – 3.15

Research Tools and Resources

Krystof Bankiewicz, MD, PhD, University of California, San Francisco 
“Image-Guided Convective Delivery of AAV Vectors” Abstract Video

Susan Bressman, MD, Beth Israel Medical Center 
“Parkinson’s Disease, Ashkenazi Jews and LRRK2” Abstract Video

Robert L. Nussbaum, MD, University of California, San Francisco 
“P1 Artificial Chromosome Transgenic Mice as models for Progressive Parkinson Disease” Abstract Video

Michael G. Schlossmacher, MD, University of Ottawa 
“Characterization of Alpha Synuclein in Human Fluids & Brain as a Biomarker for PD” Abstract Slides

3.15 – 3.45

Networking Break/Poster Viewing

3.45 – 4.45

Hot Topics in PD

Franz Hefti, PhD, Avid Radiopharmaceuticals, Inc.
“How Should One Design the First Alpha-Synuclein Efficacy Trial?” Abstract  Video

Andrew Singleton, PhD, National Institute on Aging/NIH
“(How) Can GWAS Help Drug Developers?” Abstract

4.45 – 5.00

Closing Remarks

5.00 – 7.00

Cocktail Reception/Poster Viewing

16 Sep 2009 02:06 PM EST
Mutations in the LRRK2 gene are the most common genetic cause of classic or typical Parkinson’s disease (PD). One mutation, G2019S, is especially frequent in Jewish (about 14%) and North ... 
Responses: 1
16 Sep 2009 02:11 PM EST
To date there is no readily accessible laboratory test available for the diagnosis of Parkinson's disease. The diagnosis of probable PD is generally made over time by a neurologist who serially ... 
Responses: 1
17 Sep 2009 01:37 PM EST
A small fraction are familial and caused by mutations in single genes. In particular, various missense mutations (A53T, A30P, and E46K) and copy number (duplication and triplication) mutations in ... 
Responses: 1
17 Sep 2009 01:45 PM EST
The application of genome wide association studies (GWAS) has had a clear and significant impact on our appreciation of the genetic basis of complex diseases. The NHGRI catalog of GWAS lists more ... 
17 Sep 2009 03:48 PM EST
Two years ago, in an MJFF-funded search for proteins that are neuroprotective in a simple worm model of PD, the most promising target to emerge was VPS41, believed to be involved in systems that ... 
Responses: 1
17 Sep 2009 03:51 PM EST
The progressive death of brain neurons containing the neurochemical dopamine (DA) is the hallmark of Parkinson's disease. The symptoms of PD can be improved by l-DOPA, a drug which transiently ... 
Responses: 1
30 Sep 2009 11:13 AM EST
We have identified a neurotransmitter receptor that reduces activity of a brain pathway that is overactive in PD patients. We used a library of 1.2 million drug-like molecules we to identify ... 
Responses: 1
1 Oct 2009 10:53 AM EST
Gene transfer technology holds promise to permanently alter the natural course of PD. However, in order for this technology to work there is a critical need for safe, reproducible brain ... 
Responses: 1
1 Oct 2009 11:06 AM EST
Preliminary work in our laboratories has demonstrated that siRNA is potent at reducing alpha-synuclein expression in rodent and primate brain, and supports the use of siRNA-based therapeutics in PD ... 
1 Oct 2009 11:59 AM EST
Alpha-synuclein remains one of the most compelling biological targets for Parkinson’s disease (PD).  It is present in aggregated form within Lewy bodies, a hallmark neuropathological ... 
Responses: 1
13 Oct 2009 03:59 PM EST
This is a video of Robert's slide presentation to the Therapeutics Conference, with his narration. ... 
14 Oct 2009 11:19 AM EST
This is a video of Krystof's slide presentation to the PD Therapeutics Conference, with his narration   ... 
14 Oct 2009 11:25 AM EST
This is a video of Jeff's slide presentation to the PD Therapeutics Conference, with his narration   ... 
14 Oct 2009 11:34 AM EST
This is a video of Gretchen's presentation on novel phosphodiesterase inhibitors for Parkinson's disease.     ... 
15 Oct 2009 02:17 AM EST
This is a video of Susan's slide presentation to the PD Therapeutics Conference, with her narration.     ... 
15 Oct 2009 02:26 AM EST
This is a video of Franz's slide presentation to the PD Therapeutics Conference, with his narration.         ... 
15 Oct 2009 02:11 PM EST
This is a video of David's presentation about the validation of VPS41, a protein involved in lysosomal trafficking, as a target for parkinson disease therapy.   ... 
18 Nov 2009 10:28 AM EST
Michael has provided us with an update to his slide presentation at the PD Therapeutics Conference - it is available below for download and viewing. ...